3 US Generics and Branded Medicines Company, Pain and Anti-Malarial Brands Leader and Soft Gel Capsules Producer Stocks With a Strong Future Roadmap: Alembic Pharmaceuticals, Ipca Laboratories and Strides Pharma Science

US generics, pain care brand and soft gel stocks bring together companies with a visible plan for the years ahead. Alembic Pharmaceuticals, Ipca Laboratories and Strides Pharma Science cover a US generics and branded medicines company, a pain and anti-malarial brands leader and a soft gel capsules producer.

This list covers three US generics, pain care brand and soft gel stocks with complete current figures: Alembic Pharmaceuticals, Ipca Laboratories and Strides Pharma Science. Every figure comes from the latest reported financials and the 26 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are US Generics, Pain Care Brand and Soft Gel Stocks?

US generics, pain care brand and soft gel stocks are listed drug makers that sell generics in regulated markets and trusted brands in India across pain, malaria and chronic care. Their earnings depend on launches, approvals, plant quality and prescriptions.

US Generics, Pain Care Brand and Soft Gel Stocks at a Glance

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing US generics, pain care brand and soft gel stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in US generics, pain care brand and soft gel stocks can use the coming numbers to test whether growth is holding.

Why Do US Generics, Pain Care Brand and Soft Gel Stocks Have a Strong Roadmap in India?

US generics, pain care brand and soft gel stocks have a strong roadmap in India because a wide product pipeline, trusted brands and rising healthcare access keep widening the revenue base.

• Product pipeline. New launches in regulated markets add revenue.
• Brand trust. Pain and chronic brands retain prescribers.
• Dosage forms. Oral solids and soft gels serve many markets.

Why Alembic Pharmaceuticals Features Among These US Generics, Pain Care Brand and Soft Gel Stocks

Among the US generics, pain care brand and soft gel stocks on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.

The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7.

Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore.

Roadmap: The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.

What to watch: Follow new approvals in the United States, the pace of complex generic launches and domestic growth.

Why Ipca Laboratories Features Among These US Generics, Pain Care Brand and Soft Gel Stocks

Among the Vadodara generics and anti-malarial shares on this list, Ipca Laboratories is a Mumbai-based pharmaceutical company that makes formulations and active ingredients, with leading brands in pain management, anti-malarials, cardiovascular and anti-infective therapies.

Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%.

In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0.

Roadmap: The company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.

What to watch: Monitor the growth of the branded domestic business and the capacity utilisation of its active ingredient plants.

Why Strides Pharma Science Features Among These US Generics, Pain Care Brand and Soft Gel Stocks

Among the three companies on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.

In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%.

Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.

Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.

What to watch: Track new US launches and the pace of price erosion in generic categories.

Alembic Pharmaceuticals vs Ipca Laboratories vs Strides Pharma Science on Key Financials

The table below sets the three US generics, pain care brand and soft gel stocks side by side on revenue, profit and margin, using reported figures.

Strides Pharma Science posts the highest return on equity in this group at 17.9%. Ipca Laboratories combines the largest FY26 revenue at Rs 9,821 crore with the fastest revenue growth, a 13.6% compound annual rate. A useful habit with US generics, pain care brand and soft gel stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several oral solids and chronic brand maker stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in US Generics, Pain Care Brand and Soft Gel Stocks

Every theme carries risks that deserve a check before any decision. For these US generics, pain care brand and soft gel stocks, the main points are: Long-term Vadodara generics and anti-malarial shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory checks. Plant inspections can affect approvals.
• Price pressure. Generic prices abroad can fall.
• Currency moves. Export earnings move with the rupee.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter US generics, pain care brand and soft gel stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on US Generics, Pain Care Brand and Soft Gel Stocks

US generics, pain care brand and soft gel stocks suit investors who prefer to study business strength before price moves. Alembic Pharmaceuticals, Ipca Laboratories and Strides Pharma Science each have a clear plan to grow. Based on the 26 October 2026 close, Alembic Pharmaceuticals trades at Rs 766.4, Ipca Laboratories at Rs 1,938.6 and Strides Pharma Science at Rs 1,033.1. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these US generics, pain care brand and soft gel stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track US generics, pain care brand and soft gel stocks, set price alerts and get research-backed stock ideas.

What are US generics, pain care brand and soft gel stocks?

Ans. US generics, pain care brand and soft gel stocks are listed drug makers that sell generics in regulated markets and trusted brands in India across pain, malaria and chronic care. Their earnings depend on launches, approvals, plant quality and prescriptions. This list looks at three of them, Alembic Pharmaceuticals, Ipca Laboratories and Strides Pharma Science, using reported FY22 to FY26 financials and the 26 October 2026 closing prices.

Which US generics, pain care brand and soft gel stocks are covered in this list?

Ans. This list covers Alembic Pharmaceuticals, Ipca Laboratories and Strides Pharma Science. Based on the 26 October 2026 close, Alembic Pharmaceuticals traded at Rs 766.4, Ipca Laboratories at Rs 1,938.6 and Strides Pharma Science at Rs 1,033.1. Their return on equity ranges from 11.9% to 17.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 13.6%.

Why do US generics, pain care brand and soft gel stocks have a strong future roadmap in India?

Ans. US generics, pain care brand and soft gel stocks have a strong roadmap in India because a wide product pipeline, trusted brands and rising healthcare access keep widening the revenue base. The main drivers are as follows. Product pipeline. New launches in regulated markets add revenue. Brand trust. Pain and chronic brands retain prescribers. Dosage forms. Oral solids and soft gels serve many markets. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Alembic Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.

How has Ipca Laboratories performed financially?

Ans. Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.

How has Strides Pharma Science performed financially?

Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.

What risks should investors check before buying US generics, pain care brand and soft gel stocks?

Ans. Investors should check a few risks before buying US generics, pain care brand and soft gel stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices abroad can fall. Currency moves. Export earnings move with the rupee. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of US generics, pain care brand and soft gel stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 26 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.